Emyria has received strong interest from potential participants for its study into irritable bowel syndrome (IBS).
The study will complement Emyria’s recent mental health focussed drug development program.
Up to 200 people will be included in the study, expected to last 12 months
Emyria is undertaking this observational study as an important step towards generating evidence of efficacy and safety for routinely prescribed medicinal cannabis for the management of symptoms in patients with irritable bowel syndrome (IBS), a significant unmet medical need.
This study will also inform the development of Emyria’s second cannabinoid-based drug candidate.
Emyria’s Managing Director Michael Winlo says: “We’re pleased to see strong interest in our CALM-GUT study from patients with irritable bowel syndrome. IBS can be a challenging condition to manage and the strong interest demonstrates the need for safe and effective options.
“We were encouraged to initiate this study based on an analysis of our Real-World Evidence and have designed it to support our second drug development program EMD-004. This study will also inform how we can better care for patients with this condition and we’re very pleased to be collaborating with Dr Chris Schneider, a consultant gastroenterologist based in Melbourne, on these projects.”
Professor Alistair Vickery and Dr Chris are leading the study across Victoria, NSW and Western Australia
Emyria’s drug development programs encompass unique clinical evidence packages, intellectual property and strategically developed clinical trial protocols informed by Emyria’s unique Real-World Evidence and observational trial results.
The development programs are intended to support the registration of specific medicines for specific health indications with the Therapeutic Goods Administration’s (TGA) Australian Register of Therapeutic Goods (ARTG).
For more details on CALM-GUT, click here.
